Vol. 20/No. 1

Aaron R. Hansen, BSc, MBBS, discusses progress with costimulatory immune checkpoints in oncology.

Recently, CDK 4/6 inhibitors have been changing practice in advanced HR-positive breast cancer, with 3 agents now having FDA-approved indications for use with endocrine therapy in the first-line setting.

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.

Endocrine therapy, commonly used for lengthy periods in the adjuvant treatment of patients with breast cancer, does not have a detrimental effect on cognitive function in survivors of early-stage disease.

Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.

When it works, immunotherapy can dramatically outperform standard of care—for some cancer types, in ways thought unattainable a decade ago.

Improvements and greater familiarity with artificial intelligence will lead to systems of checks and balances that will create trust and fulfill the promise of computer-assisted precision medicine.

Novel agents are showing impressive ability to cross the blood–brain barrier and impair tumor development in several malignancies, raising the prospect of achieving a long-elusive goal of anticancer therapy.

During a recent OncLive Peer Exchange®, a panel of CRC experts discussed the heterogeneity of metastatic CRC and the need to identify patient subsets within this disease to enable a precision medicine approach.

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.